Literature DB >> 29091529

Linking Quality and Spending to Measure Value for People with Serious Illness.

Andrew M Ryan1,2, Phillip E Rodgers2,3.   

Abstract

BACKGROUND: Healthcare payment is rapidly evolving to reward value by measuring and paying for quality and spending performance. Rewarding value for the care of seriously ill patients presents unique challenges.
OBJECTIVE: To evaluate the state of current efforts to measure and reward value for the care of seriously ill patients.
DESIGN: We performed a PubMed search of articles related to (1) measures of spending for people with serious illness and (2) linking spending and quality measures and rewarding performance for the care of people with serious illness. We limited our search to U.S.-based studies published in English between January 1, 1960, and March 31, 2017. We supplemented this search by identifying public programs and other known initiatives that linked quality and spending for the seriously ill and extracted key program elements.
RESULTS: Our search related to linking spending and quality measures and rewarding performance for the care of people with serious illness yielded 277 articles. We identified three current public programs that currently link measures of quality and spending-or are likely to within the next few years-the Oncology Care Model; the Comprehensive End-Stage Renal Disease Model; and Home Health Value-Based Purchasing. Models that link quality and spending consist of four core components: (1) measuring quality, (2) measuring spending, (3) the payment adjustment model, and (4) the linking/incentive model. We found that current efforts to reward value for seriously ill patients are targeted for specific patient populations, do not broadly encourage the use of palliative care, and have not closely aligned quality and spending measures related to palliative care.
CONCLUSIONS: We develop recommendations for policymakers and stakeholders about how measures of spending and quality can be balanced in value-based payment programs.

Entities:  

Keywords:  healthcare payment for serious illness; measuring value of care; rewarding performance; serious illness; spending performance

Mesh:

Year:  2017        PMID: 29091529      PMCID: PMC5756459          DOI: 10.1089/jpm.2017.0496

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  49 in total

Review 1.  The effect of accountable care organizations on oncology practice.

Authors:  Lawrence N Shulman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

2.  Changes in Medicare costs with the growth of hospice care in nursing homes.

Authors:  Pedro Gozalo; Michael Plotzke; Vincent Mor; Susan C Miller; Joan M Teno
Journal:  N Engl J Med       Date:  2015-05-07       Impact factor: 91.245

3.  Analyzing the Impact of Palliative Care Interventions on Cost of Hospitalization: Practical Guidance for Choice of Dependent Variable.

Authors:  Peter May; Charles Normand
Journal:  J Pain Symptom Manage       Date:  2016-05-18       Impact factor: 3.612

4.  Racial and Ethnic Differences in End-of-Life Medicare Expenditures.

Authors:  Elena Byhoff; John A Harris; Kenneth M Langa; Theodore J Iwashyna
Journal:  J Am Geriatr Soc       Date:  2016-09-01       Impact factor: 5.562

5.  Comparison of Site of Death, Health Care Utilization, and Hospital Expenditures for Patients Dying With Cancer in 7 Developed Countries.

Authors:  Justin E Bekelman; Scott D Halpern; Carl Rudolf Blankart; Julie P Bynum; Joachim Cohen; Robert Fowler; Stein Kaasa; Lukas Kwietniewski; Hans Olav Melberg; Bregje Onwuteaka-Philipsen; Mariska Oosterveld-Vlug; Andrew Pring; Jonas Schreyögg; Connie M Ulrich; Julia Verne; Hannah Wunsch; Ezekiel J Emanuel
Journal:  JAMA       Date:  2016-01-19       Impact factor: 56.272

6.  Capitated risk-bearing managed care systems could improve end-of-life care.

Authors:  J Lynn; A Wilkinson; F Cohn; S B Jones
Journal:  J Am Geriatr Soc       Date:  1998-03       Impact factor: 5.562

7.  Regional variation in the association between advance directives and end-of-life Medicare expenditures.

Authors:  Lauren Hersch Nicholas; Kenneth M Langa; Theodore J Iwashyna; David R Weir
Journal:  JAMA       Date:  2011-10-05       Impact factor: 56.272

8.  Development and validation of hospital "end-of-life" treatment intensity measures.

Authors:  Amber E Barnato; Max H Farrell; Chung-Chou H Chang; Judith R Lave; Mark S Roberts; Derek C Angus
Journal:  Med Care       Date:  2009-10       Impact factor: 2.983

9.  Acute hospital care is the chief driver of regional spending variation in Medicare patients with advanced cancer.

Authors:  Gabriel A Brooks; Ling Li; Hajime Uno; Michael J Hassett; Bruce E Landon; Deborah Schrag
Journal:  Health Aff (Millwood)       Date:  2014-10       Impact factor: 6.301

10.  Impact of a New Palliative Care Program on Health System Finances: An Analysis of the Palliative Care Program Inpatient Unit and Consultations at Johns Hopkins Medical Institutions.

Authors:  Sarina R Isenberg; Chunhua Lu; John McQuade; Kelvin K W Chan; Natasha Gill; Michael Cardamone; Deirdre Torto; Terry Langbaum; Rab Razzak; Thomas J Smith
Journal:  J Oncol Pract       Date:  2017-02-28       Impact factor: 3.714

View more
  3 in total

1.  Accountability for Community-Based Programs for the Seriously Ill.

Authors:  Joan M Teno; Russ Montgomery; Tom Valuck; Janet Corrigan; Diane E Meier; Amy Kelley; J Randall Curtis; Ruth Engelberg
Journal:  J Palliat Med       Date:  2017-12-01       Impact factor: 2.947

2.  Cardiologist Participation in Accountable Care Organizations and Changes in Spending and Quality for Medicare Patients With Cardiovascular Disease.

Authors:  Devraj Sukul; Andrew M Ryan; Phyllis Yan; Adam Markovitz; Brahmajee K Nallamothu; Valerie A Lewis; John M Hollingsworth
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2019-09-16

3.  Igniting Harmonized Digital Clinical Quality Measurement through Terminology, CQL, and FHIR.

Authors:  Robert C McClure; Caroline L Macumber; Julia L Skapik; Anne Marie Smith
Journal:  Appl Clin Inform       Date:  2020-01-08       Impact factor: 2.342

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.